Unfortunately, as has been a common theme in clinical studies evaluating targeted agents for the treatment of metastatic colorectal cancer, we were unable to clearly identify a subset of CRC that is more (or more consistently) responsive to the combination of a MEK and Aurora A kinase inhibitor. Here, AURKA is linked to metastatic colorectal cancer.